Volume 12, Issue 3 (Vol.12 No.3 Oct 2023)                   rbmb.net 2023, 12(3): 359-365 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbood A, Majeed Hameed R, Ghazi Al Safi W. Neuregulin 4 in Polycystic Ovarian Syndrome (PCOS) Phenotypes: A Key Role or Standby. rbmb.net 2023; 12 (3) :359-365
URL: http://rbmb.net/article-1-1220-en.html
Department of Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq.
Abstract:   (861 Views)
Background: Neuregulin_4 (NRG4) is one of the adipokines members that synthesize adipose tissues. It has an activating effect on epidermal growth factor receptors (ErbB receptors). NRG4 has indirect effects on the hormonal environment through its interaction to ErbB receptors. Increased insulin resistance and chronic low-grade inflammation may be present when NRG4 levels are high in PCOS. Obesity and polycystic ovarian syndrome have recently gained a lot of attention. However, the literature on the connection between NRG4 and the PCOS phenotype is limited. Thus, this research aimed to identify neuregulin_4's function as a biomarker for insulin resistance in PCOS phenotypes.

Methods: A case-control study and included 140 female cases effect by different phenotypes of PCOS. Patients samples were collected at the reproductive fertility consultant of the Teaching Hospital for Obstetrics and Gynecology, Kerbala health directorate, Iraq. The outpatient clinic serum hormonal levels and insulin concentration were determined by the electrochemiluminescence immunoassay “ECLIA” system. Elisa system was used for the detection of Neuregulin-4 protein level.

Results: At the early age of participant NRG4 was increased significantly in all phenotypes of PCOS compared to control with a P< 0.05. interestingly, phenotype A was shown high level of NRG4 following phenotype C than phenotype D and phenotype B. Receiver Operator Characteristic Curves (ROC) analysis for NRG4 was performed and showed good diagnostic performers to word phenotype A.

Conclusion: Females with phenotype A have a higher level of NRG4 than other phenotypes, which could be attributable to the more pronounced metabolic abnormalities in this phenotype.
Full-Text [PDF 267 kb]   (455 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2023/08/10 | Accepted: 2023/09/15 | Published: 2024/02/25

References
1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. [DOI:10.1007/s11906-018-0812-z] [PMID] []
2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. [DOI:10.1016/j.metabol.2018.09.005] [PMID]
3. Czerwińska M, Czarzasta K, Cudnoch-Jędrzejewska A. New Peptides as Potential Players in the Crosstalk Between the Brain and Obesity, Metabolic and Cardiovascular Diseases. Front Physiol. 2021;12:692642. [DOI:10.3389/fphys.2021.692642] [PMID] []
4. Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications. Int J Mol Sci. 2020;21(10):3570. [DOI:10.3390/ijms21103570] [PMID] []
5. Landecho MF, Tuero C, Valentí V, Bilbao I, de la Higuera M, Frühbeck G. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk. Nutrients. 2019;11(11):2664. [DOI:10.3390/nu11112664] [PMID] []
6. Al-Lami HB, Al-Tu'ma F J, Al-Safi WG. Association between anti-Müllerian hormone and other biomarkers with ovarian function in polycystic ovarian syndrome of Iraqi women. J Contemp Med Sci. 2020;6(4).‏ [DOI:10.22317/jcms.v6i4.824]
7. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019;92:108-120. [DOI:10.1016/j.metabol.2018.11.002] [PMID]
8. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. [DOI:10.1093/humrep/dey256] [PMID] []
9. Moran LJ, Tassone EC, Boyle J, Brennan L, Harrison CL, Hirschberg AL, et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: Lifestyle management. Obes Rev. 2020;21(10):e13046. [DOI:10.1111/obr.13046] [PMID]
10. Polak AM, Adamska A, Krentowska A, Łebkowska A, Hryniewicka J, Adamski M, Kowalska I. Body Composition, Serum Concentrations of Androgens and Insulin Resistance in Different Polycystic Ovary Syndrome Phenotypes. J Clin Med. 2020;9(3):732. [DOI:10.3390/jcm9030732] [PMID] []
11. Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocr Metab Res. 2020;12:66-71. [DOI:10.1016/j.coemr.2020.03.004]
12. Tutunchi H, Ostadrahimi A, Hosseinzadeh-Attar MJ, Miryan M, Mobasseri M, Ebrahimi-Mameghani M. A systematic review of the association of neuregulin 4, a brown fat-enriched secreted factor, with obesity and related metabolic disturbances. Obes Rev. 2020;21(2):e12952. [DOI:10.1111/obr.12952] [PMID]
13. Gumà A, Martínez-Redondo V, López-Soldado I, Cantó C, Zorzano A. Emerging role of neuregulin as a modulator of muscle metabolism. Am J Physiol Endocrinol Metab. 2010;298(4):E742-50. [DOI:10.1152/ajpendo.00541.2009] [PMID]
14. Liu Y, Chen M. Neuregulin 4 as a novel adipokine in energy metabolism. Front Physiol. 2023;13:1106380. [DOI:10.3389/fphys.2022.1106380] [PMID] []
15. Chen W, Pang Y. Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites. 2021;11(12):869. [DOI:10.3390/metabo11120869] [PMID] []
16. Bahadur A, Verma N, Mundhra R, Chawla L, Ajmani M, Sri MS, Arora S. Correlation of Homeostatic Model Assessment-Insulin Resistance, Anti-Mullerian Hormone, and BMI in the Characterization of Polycystic Ovary Syndrome. Cureus. 2021;13(6):e16047. [DOI:10.7759/cureus.16047]
17. Ayoob LA. Evaluation of serum Neuregulin4 level in Polycystic ovary syndrome patients. Eurasian Med Res Period. 2022;13:7-10.‏
18. Kurek Eken M, Sahin Ersoy G, Yayla Abide C, Sanverdi İ, Devranoglu B, Kutlu T, Çevik Ö. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. J Obstet Gynaecol. 2019;39(7):975-980 [DOI:10.1080/01443615.2019.1581754] [PMID]
19. Temur M, Calan M, Akşit M, Yılmaz Ö, Çift T, Akselim B, et al. Increased serum neuregulin 4 levels in women with polycystic ovary syndrome: A case-control study. Ginekol Pol. 2017;88(10):517-522. [DOI:10.5603/GP.a2017.0095] [PMID]
20. Cao S, Hu Y. Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome. Biosci Rep. 2021;41(9):BSR20211658. [DOI:10.1042/BSR20211658] [PMID] []
21. Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017;37(8):1036-1047. [DOI:10.1080/01443615.2017.1318840] [PMID]
22. Ariaee N, Farid R, Shabestari F, Shabestari M, Jabbari Azad F. Trace Elements Status in Sera of Patients with Allergic Asthma. Rep Biochem Mol Biol. 2016;5(1):20-25.
23. Shenta A, Saud K, Al-Shawi A. Assessment the Correlations of Hormones, Lipid Profiles, Oxidative Stress, and Zinc Concentration in Iraqi Women with Polycystic Ovary Syndrome. Rep Biochem Mol Biol. 2020;9(3):270-277. [DOI:10.29252/rbmb.9.3.270] [PMID] []

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb